Literature DB >> 7427960

Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

H K Adam, J S Patterson, J V Kemp.   

Abstract

The densitometric analytic procedure used for tamoxifen can also be used to quantify its desmethyl metabolite. In a study involving six healthy male volunteers, tamoxifen tablets were shown to be as bioavailable as a solution of tamoxifen citrate. After administration of a single dose of 20 mg, peak serum levels of tamoxifen were 42 ng/ml; those of the metabolite were 12 ng/ml. The half-lives of the drug and metabolite were approximately 4 and 9 days, respectively, after a single dose. After three widely separated single doses, a reversible increase in elimination half-life occurred.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7427960

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

1.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 3.  Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.

Authors:  Rajiv P Parikh; Elizabeth B Odom; Liyang Yu; Graham A Colditz; Terence M Myckatyn
Journal:  Breast Cancer Res Treat       Date:  2017-02-09       Impact factor: 4.872

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

5.  Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study.

Authors:  M Napolitano; F Keime-Guibert; A Monjour; C Lafitte; A Ameri; P Cornu; P Broët; J Y Delattre
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 6.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Authors:  L Löfgren; B Wallberg; N Wilking; T Fornander; L E Rutqvist; K Carlström; B von Schoultz; E von Schoultz
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 8.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.

Authors:  P M Wilkinson; G G Ribiero; H K Adam; J V Kemp; J S Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

10.  Effect of continuous vs intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1.

Authors:  M Dietel; R Löser; P Röhlke; W Jonat; A Niendorf; D Gerding; A Kohr; F Hölzel; H Arps
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.